Board of Directors
Executive Chairman | Pietro Puglisi, MBA
Pietro is a biomedical engineer with over a decade of experience in life sciences investments and innovation.
He is a founding partner at Claris Ventures, investment firm based in Turin (Italy), with focus on early-stage biotech ventures.
He is currently a board member of several biotech companies including Neophore, Repron Therapeutics, Kither Biotech, Resalis Therapeutics, Heqet Therapeutics and Lever Bio. Pietro started his career at LifeSciences Consultants and later joined Innogest VC firm’s healthcare practice.
He received an M.Sc. in Biomedical Engineering from Politecnico di Torino (Italy) and an MBA from Collége des Ingenièurs (France/Italy).
Independent Board Member | Adi Hoess, M.D., PhD
Dr. Hoess brings over three decades of leadership experience from across the biopharmaceutical industry and a significant commitment to the development of immuno-oncology therapeutics. As the former Chief Executive Officer of Affimed N.V., he played a pivotal role in advancing groundbreaking therapies that harness the immune system to combat cancer, aligning with ALKemist Bio’s mission.
In addition to 13 years as CEO of Nasdaq-listed Affimed, he currently serves as the Chief Executive Officer of ViaNautis, a company pioneering targeted delivery solutions for genetic medicines. He was also Chief Commercial Officer of Jerini, which was acquired by Shire. He started his career at MorphoSys, attaining the title of Vice President Licensing and Business Development, where he oversaw multiple in- and out-licensing deals. Dr. Hoess holds a a medical degree from the Technical University of Munich and a PhD in Chemistry and Biochemistry from Munich University.